283 Photodynamic therapy for basal cell carcinoma enhanced by pretreatment with oral vitamin D: interim results of a prospective clinical trial

Photodynamic therapy (PDT) is used in Europe to treat basal cell carcinoma (BCC), but it not approved the USA due uncertainties about efficacy. Vitamin D3 (VD3; cholecalciferol) treatment prior PDT improves BCC responses mice. A prospective, double-blind, crossover clinical trial [NCT03467789] was designed test whether oral VD3 pretreatment enhances response blue light PDT. Participants received 3 treatments (20% ALA, 4 h; 417 nm, 30 min) 2 months apart. High-dose or placebo administered each of first two sessions. Lesions were recorded with a 3D digital camera allow software-assisted tumor volume analysis. Treatment-resistant tumors biopsied at final visit. To date, 24 patients and 128 BCCs have been analyzed. Two-thirds (70%) all lesions cleared completely after Of 30% that failed clear, except one superficial either nodular, micronodular, adenoid, infiltrative subtypes. assess ability neoadjuvant potentiate efficacy, we evaluated available determine their relative reduction VD3+PDT placebo+PDT. Tumors fulfilled prediction shrinkage (% reduction) would be greater compared placebo+PDT scored as “Yes”. In our analysis, 15 “Yes” 6 “No”. This >2-fold difference provides preliminary evidence augments therapeutic responsiveness for many tumors. may an effective BCC, especially BCC. Oral given represents novel safe combination approach.